Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Beth

Gilead and Galapagos discontinuing IPF Phase III front-runner is a major setback in the disease space

Gilead and Galapagos recently announced the discontinuation of the ISABELA Phase III clinical trials investigating ziritaxestat, a once daily autotaxin inhibitor formerly known as GLPG-1690, in patients with idiopathic pulmonary fibrosis (IPF). Due to IPF’s high clinical unmet needs, this discontinuation represents a major setback in the disease space, according to GlobalData, a leading data […]
Read more

US dominates upcoming oil and gas project starts in North America by 2025

The US will drive upcoming project starts across the oil and gas value chain in North America, accounting for 70% of the total projects expected to start operations by 2025. Of these, new build projects dominate with 83%, while the remaining are expansion projects mainly in the upstream sector (fields, excluding shale), according to GlobalData, a leading data, and analytics company. GlobalData’s report, ‘North America Oil and Gas Projects Outlook to 2025 – Development Stage, Capacity, Capex and Contractor Details of All New Build and Expansion Projects’, reveals that 417 projects […]
Read more

Ford is the latest car company to bite the electric bullet

Following the news that Ford has unveiled a new ramped-up electrification strategy that includes making all its passenger cars sold in Europe zero emissions capable by mid-2026 and transforming its Cologne site into a hub for electric car manufacturing; David Leggett, Automotive Analyst at GlobalData, a leading data and analytics company, offers his view: “Ford […]
Read more

US continues to top cross-border M&A activity

The US secured the top spots in terms of outbound and inbound mergers and acquisitions (M&A) deal volume and value in 2020, despite witnessing a decline in activity during the COVID-hit 2020. Meanwhile, China continued to remain attractive to foreign investors and emerged as a notable exception to witness growth in inbound M&A activity, according […]
Read more

Tidepool Loop app will be game-changing for type 1 diabetes management

If Tidepool’s diabetes management app Tidepool Loop gains its 510(k) clearance from the Food and Drug Administration (FDA), it will have a significant impact on patients’ ability to attain glycemic control, says GlobalData, a leading data and analytics company. This is especially prominent as only 20-30% of type 1 diabetes (T1D) patients meet their glycemic […]
Read more

Transformation of stock exchanges will be a boon for fintech

The rise of private securities marketplaces is likely to mark the beginning of the end for the national stock exchange monopolies. It will herald a chance for challenger banks and fintech to take advantage of lower funding costs from individual, accredited investors, says GlobalData, a leading data and analytics company. Katherine Long, Banking Analyst at […]
Read more

Western Europe’s car market looking up

GlobalData forecasts the Western European light vehicle market at 15 million in 2021, 20.3% ahead of 2020 but still over 1.3 million units short of 2019’s market level. Calum MacRae, Automotive Analyst at GlobalData, comments: “The year was off to a tough start with vehicle sales in January across Europe heavily impacted by pandemic-related population […]
Read more

New COVID-19 strains are causing clinical trial resumptions to slow

Many clinical trials were set to resume activity as the initial peak of the COVID-19 virus started declining. However, with the number of confirmed COVID-19 cases rising globally, especially in Western areas such as the US and Europe, along with two more infectious variants of COVID-19, this has led to increased restrictive measures and has […]
Read more

AstraZeneca/Oxford’s COVID-19 vaccine could see increased global uptake after strong efficacy results

The primary analysis of AstraZeneca/Oxford’s vaccine is likely to put pressure on other companies to demonstrate reductions in transmission as soon as possible, says GlobalData, a leading data and analytics company. Arafa Salam, PhD, Infectious Diseases Analyst at GlobalData, comments: “While the efficacy profile of Pfizer/BioNtech may be higher after the second dose, the AstraZeneca/Oxford […]
Read more

Biogen’s main MS assets facing increasing competition and further losses in the MS market

Biogen recently announced Food and Drug Administration (FDA) approval of its new intramuscular (IM) injection route of administration for Plegridy (peginterferon beta-1a) for the treatment of relapsing forms of multiple sclerosis (MS). This new formulation will enable Biogen to expand its MS portfolio, while also reducing the side effects from the subcutaneous way of administration […]
Read more

Nissan strategic plan is on track

Following the news that Nissan has returned to a positive operating profit of 27.1 billion yen for the quarter ended 31 December 2020, David Leggett, Automotive Analyst at GlobalData, a leading data and analytics company, offers his view: “The swing to operating profit for the latest quarterly financials is a sign that Nissan is now […]
Read more
1 … 40 41 42 43 44 … 93